care

Dermatological Skincare net sales for the first nine months were 1,063 million USD, with year-on-year growth of 8.2% at constant currency.

Galderma outgrew the market in Dermatological Skincare globally, with the majority of key markets gaining share, despite some constrained consumer spending. Growth in Dermatological Skincare was led by International markets, where both Cetaphil®and Alastin®grew double-digit. Cetaphil continued on its very strong trajectory, with an outstanding performance in fast-growing Asian markets. In the U.S., Alastin also delivered double-digit growth, while Cetaphil saw positive responses late in the third quarter from the multiple promotional activities rolled out ahead of the high year-end season.

To capture opportunities in Dermatological Skincare and drive further growth, Galderma expanded its portfolio with innovation addressing white spaces. This includes two transformative Cetaphil launches in the U.S. creatin
=*=*=*=*=*=
当前为第7/31页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页